Empagliflozin a winner in challenging arena of stabilized acute HF
November 19, 2021
Early in-hospital initiation of SGLT2 inhibitors “should be considered the new standard of care” in most patients with heart failure regardless of their ejection fraction, says an expert observer.
Ticagrelor reversal agent achieves quick hemostasis: REVERSE-IT
November 17, 2021
The monoclonal antibody bentracimab, which can rapidly reverse ticagrelor, was found effective and safe in an FDA-requested interim analysis of a phase 3 trial.
Cardiogenic shock teams again tied to lower mortality
September 23, 2021
New data suggest centers with a shock team had higher survival and lower resource use in the cardiac ICU.
Growing proportion of cardiac arrests in U.S. considered opioid related
September 10, 2021
Due to a steep rise, opioid-associated cardiac arrests have become a major public health issue.
Docs fight back after losing hospital privileges, patients, and income
August 10, 2021
Physicians in St. Louis lost their hospital privileges when the hospital entered into an exclusive contract with other physicians. They’re losing patients and money.
ESC heart failure guideline to integrate bounty of new meds
July 29, 2021
It has a simple answer to a seemingly complex issue: how to merge the newly approved with mainstay drug therapies. And it conditionally okays meds in a group long without guideline-directed options.
Statins again linked to lower COVID-19 mortality
July 21, 2021
Patients hospitalized for COVID-19 who had been taking statins had a substantially lower risk of death and severe outcomes than those who weren’t in a large observational study.
Simple risk assessment predicts post-PCI ischemic events
June 15, 2021
Determining if PCI patients have just one or more guideline-based risk features predicts their odds of ischemic events, and can be used to tailor antiplatelet therapy, suggests a real-world analysis.
Are left atrial thrombi that defy preprocedure anticoagulation predictable?
June 11, 2021
Features that predispose to such persistent LA thrombi, which are not very rare, could potentially guide more targeted TEE screening before rhythm-control procedures.
Single subcutaneous shot offers fast, potent platelet inhibition in STEMI
June 1, 2021
The effect was seen within 15 minutes of receiving RUC-4, an investigational glycoprotein IIb/IIIa inhibitor, with no thrombocytopenia, in a phase 2a study.